We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.52B
AUM Growth
-$648M
Cap. Flow
+$87.1M
Cap. Flow %
1.58%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$349M
2
PGNY icon
Progyny
PGNY
+$22.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Miscellaneous 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMIC
126
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$2.06M 0.04%
18,023
-58,670
-76% -$6.88M
HLSQ
127
Tessera Defense and Homeland Security Inc.
HLSQ
$2.65M
$2.05M 0.04%
1,481
– –
GH icon
128
CALL
Guardant Health
GH
$23.9B
$2.02M 0.04%
+50,000
New +$2.48M
KALV
129
DELISTED
KalVista Pharmaceuticals
KALV
$1.82M 0.03%
+185,400
New +$2.05M
SGHT icon
130
Sight Sciences
SGHT
$452M
$1.8M 0.03%
200,000
– –
EYPT icon
131
EyePoint Inc
EYPT
$323M
$1.69M 0.03%
+214,100
New +$2.15M
SRPT icon
132
Sarepta Therapeutics
SRPT
$2.21B
$1.5M 0.03%
20,000
-19,100
-49% -$1.41M
XFOR icon
133
X4 Pharmaceuticals
XFOR
$357M
$1.33M 0.02%
45,795
– –
SONX
134
DELISTED
Sonendo, Inc.
SONX
$1.24M 0.02%
723,478
-1,244,702
-63% -$3.32M
TRML
135
DELISTED
Tourmaline Bio
TRML
$1.06M 0.02%
23,600
-1,124
-5% -$88.7K
VIGL
136
DELISTED
Vigil Neuroscience
VIGL
$1.06M 0.02%
411,191
– –
SYRE icon
137
Spyre Therapeutics
SYRE
$7.94B
$908K 0.02%
71,889
-46,356
-39% -$1.62M
LBPH
138
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$351K 0.01%
113,500
– –
APTX
139
DELISTED
Aptinyx Inc. Common Stock
APTX
$300K 0.01%
538,500
– –
CABA icon
140
Cabaletta Bio
CABA
$446M
– –
-577,509
Closed -$1.17M
DXCM icon
141
DexCom
DXCM
$32.8B
– –
-599,600
Closed -$76.7M
LKFT
142
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
– –
-208,225
Closed -$12.9M
ILMN icon
143
Illumina
ILMN
$34.2B
– –
-46,363
Closed -$15.8M
NBP
144
NovaBridge Biosciences American Depositary Shares
NBP
$184M
– –
-111,120
Closed -$1.8M
PYXS icon
145
Pyxis Oncology
PYXS
$280M
– –
-143,640
Closed -$580K
RARE icon
146
Ultragenyx Pharmaceutical
RARE
$1.29B
– –
-227,600
Closed -$16.5M
EXAI
147
DELISTED
Exscientia Plc American Depositary Shares
EXAI
– –
-125,000
Closed -$1.8M
ASLN
148
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-48,530
Closed -$1.75M
NSTG
149
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-1,157,387
Closed -$40.2M
REUN
150
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
– –
-115,386
Closed -$762K
3 4 5
6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52B, down 11% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed's Q2 2022 filing shows 15 new, 26 increased, 36 reduced and 15 closed positions. Its largest new stake was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M. The largest sale was DexCom, an estimated $76.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2022 buy was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52B portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.